



Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards

Cambridge, UK, 16 June 2017 – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, is pleased to announce it won the “Emerging Star of the Year” award at last night’s European Mediscience Awards.

Crescendo was nominated for its transformational year in which the company transitioned from a technology platform company to a developer of Humabody® therapeutics, an innovative approach in the immuno-oncology field which was validated through a commercial partnership with Takeda worth up to US\$790m.

Dr. Peter Pack, CEO of Crescendo Biologics commented:

“The competition for this year’s “Emerging Star” category was particularly fierce, with a number of high caliber companies within the biotech sector being nominated. With our robust pipeline of intrinsically differentiated, multi-functional therapeutics in the oncology space, our collaboration with Takeda endorsed our pioneering approach. We look forward to leveraging the capabilities of our transgenic platform through our partnership with Takeda and new partnership opportunities over the next 12 months.”

The European Mediscience Awards, sponsored by Kempen & Co, is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies. The event recognizes the importance of the capital markets to fund growth and innovation.

Other finalists in 2017 were AiCuris Anti-Infective Cures, Artios Pharma, Blue Earth Diagnostics, Crescendo Biologics, F-star Biotechnology, Immunocore, PsiOxus Therapeutics, and Quanta Dialysis Technologies. Past winners include Biontech, Immunocore, Curetis, and Horizon Discovery Group.

Ends

For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO

Tel:44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners
Dr Christelle Kerouedan / Melanie Toyne-Sewell

Tel:44 (0)20 7457 2020
crescendo@instinctif.com



Notes to Editors

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com.

About Humabody[®] Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody[®] V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies[®] offer a unique combination of potential benefits resulting from their broad structural diversity, small size, high yield and robust biophysical properties. These attributes allow Crescendo to configure an almost limitless range of multi-specific and multi-functional Humabody[®] formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody[®]-based therapeutics in oncology. Next-generation multi-specific Humabody[®] IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response as well as specific targeting of IO modulators into the tumor-microenvironment, enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Humabody[®] Drug Conjugates (HDCs) demonstrate a superior therapeutic index to standard ADCs.

For more information, please visit the website: www.crescendobiologics.com/humabody.